Recombinant CD79a Antibody [IGA/1790R] | 33-837

Recombinant CD79a Antibody [IGA/1790R] | 33-837 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat, Monkey, Pig, Bovine

Homology: N/A

Immunogen: Amino acids 202-216 (GTYQDVGSLNIADVQ) were used as the immunogen for the recombinant CD79a antibody.

Research Area: Cancer, Immunology, Signal Transduction

Tested Application: WB, IHC-P

Application: Western blot: 0.5-1 ug/ml
Immunohistochemistry (FFPE) : 1-2ug/ml for 30 min at RT
Prediluted IHC only format: incubate for 30 min at RT

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein A affinity chromatography

Clonality: Recombinant Monoclonal

Clone: IGA/1790R

Isotype: IgG, k

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: B-cell antigen receptor complex-associated protein alpha chain, Ig-alpha, MB-1 membrane glycoprotein, Membrane-bound immunoglobulin-associated protein, Surface IgM-associated protein, CD79a, CD79A, IGA, MB1

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20) . This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.